

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-10: (Withdrawn)

Claim 11. (Currently Amended) A method of preventing or treating a ~~disorder characterized by amyloid deposition~~ Alzheimer's disease in a mammalian subject, comprising administering to the subject a dosage of ~~an agent~~ synuclein or a fragment thereof effective to produce an immune response comprising anti-synuclein antibodies against an amyloid component characteristic of said disorder and an adjuvant that augments the immune response to the synuclein, and thereby preventing or treating the disease.

Claims 12-14: (Canceled)

Claim 15. (Currently Amended) The method of claim ~~13~~ 11, wherein said ~~amyloid component~~ synuclein or fragment thereof is a ~~is selected from the group consisting of~~ AA, AL, ATTR, ApoA1, Alys, Agel, AeyS, A β , AB₂M, ASer, Acal, AIAPP and synuclein-NAC fragment.

Claims 16-17: (Canceled)

Claim 18. (Currently Amended) The method of claim ~~17~~ 11, wherein said administering ~~includes~~ further comprises administering ~~at least two amyloid fibril components~~ A β or a fragment thereof.

Claim 19. (Currently Amended) The method of claim 11, wherein said ~~agent~~ is a peptide synuclein or fragment thereof is linked to a carrier protein.

Claim 20. (Canceled)

Claim 21. (Currently Amended) The method of claim 2011, wherein said adjuvant is selected from the group consisting of QS21, monophosphoryl lipid, and alum and Freund's adjuvant.

Claim 22. (Currently Amended) The method of claim 11, wherein said ~~immunological~~ immune response is characterized by a serum titer of the anti-synuclein antibodies of at least 1:1000 with respect to said ~~amyloid component~~ A β .

10
A
Claim 23. (Currently Amended) The method of claim 22, wherein said serum titer of the anti-synuclein antibodies is at least 1:5000 with respect to said ~~fibril~~ component A β .

Claim 24. (Currently Amended) The method of claim 11, wherein said ~~immunological~~ immune response is characterized by a serum ~~amount~~ titer of ~~immunoreactivity~~ anti- synuclein antibodies corresponding to greater than about four times higher than a serum ~~level~~ titer of ~~immunoreactivity~~ anti- A β antibodies of measured in a pre-treatment control serum sample.

Claim 25. (Original) The method of claim 24, wherein said serum ~~amount of~~ immunoreactivity titer of the antibodies is measured at a serum dilution of about 1:100.

Claims 26-57: (Canceled)
